What does Reslizumab (Cinqair) do in plain English—and how does it work inside your body?
Reslizumab is an FDA-regulated Interleukin-5 Antagonist (RxNorm RxCUI 1746893). Mechanistically, 12.1 Mechanism of Action Reslizumab is an interleukin-5 antagonist (IgG4, kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Reslizumab binds to IL-5 with a dissociation constant of 81 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil surface. Inflammation is an important component in the pathogenesis of asthma. [1][2].
When your doctor writes a prescription for Reslizumab (RxNorm RxCUI 1746893, also dispensed under brand names including Cinqair), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, 12.1 Mechanism of Action Reslizumab is an interleukin-5 antagonist (IgG4, kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Reslizumab binds to IL-5 with a dissociation constant of 81 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil surface. Inflammation is an important component in the pathogenesis of asthma. [2].
Across real-world patient logs on dotMD (83% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Reslizumab tablet bottle and confirm with your pharmacist that it matches your prescribed strength (10 mg/mL Injection, Solution, Concentrate, 3 mg).